Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by robust demand ...

Regeneron topped Wall Street estimates for second-quarter results on Friday, on robust demand for its blockbuster eczema drug ...

Regeneron Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a double-digit profit ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,030.00. The company’s shares closed yesterday at $686.33.

Regeneron Pharmaceuticals Inc. Annual stock financials by MarketWatch. View the latest REGN financial statements, income statements and financial ratios.

Jefferies analyst Akash Tewari maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,200.00. The company’s shares opened today at $710.20.